EMG
GTHX

Ellington Management Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Ellington Management Group’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-17,300
Closed -$191K – 467
2020
Q1 		$191K Buy
+17,300
New +$323K 0.04% 444
2018
Q1 		– Sell
-14,800
Closed -$294K – 1058
2017
Q4 		$294K Buy
+14,800
New +$318K 0.05% 376

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Ellington Management Group's GTHX Position: Q2 2020 in Review

Ellington Management Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2020, closing a stake of 17,300 shares — an estimated $191K sold.

Ellington Management Group first reported a position in GTHX in Q4 2017 and held it in 2 quarters. The position peaked at $294K in Q4 2017. 100 funds tracked by Wall St. Rank hold GTHX as of Q2 2020.

  • Ellington Management Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Ellington Management Group sold 17,300 G1 Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $191K.
  • Ellington Management Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Ellington Management Group's G1 Therapeutics, Inc. Common Stock position peaked at $294K in Q4 2017.
  • 100 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.